Bladder cancer is among the most expensive diseases in oncology in terms of treatment costs – each procedure requires days of hospitalization and recurrence rates are high. Current unmet clinical needs can be addressed by optical methods due to the combination of non-invasive and real-time capture of unprecedented biomedical information. The objective of the H2020 project MIB is to provide robust, easy-to-use, cost-effective optical methods with high sensitivity and specificity, to enable a step-change in point-of-care diagnostics of bladder cancer. The concept relies on combining optical methods – optical coherence tomography, multi-spectral opto-acoustic tomography, shifted excitation Raman difference spectroscopy, and multiphoton microscopy – providing structural, biochemical and functional information. The consortium comprises of FBH and other world-leading academic organizations in a strong, unique partnership with innovative SMEs and clinical end-users.
The FBH and its Laser Sensors Lab are developing laser light sources for two optical diagnostic methods – Shifted Raman Difference Spectroscopy (SERDS) and multiphoton microscopy (MPM). The diode laser module for SERDS will be realized as a dual-wavelength Y-branch DBR tapered diode laser emitting over 1 W at 785 nm. The two emitted wavelengths of the laser module can be adjusted to the targeted Raman signal with the implemented resistor heaters next to the higher order DBR gratings. For the second diagnostic method MPM, a DBR-tapered diode laser and monolithic MOPA with over 5 W output power at 1064 nm suitable for applications as high power second harmonic generation will be developed.
MIB (duration 01.01.2016 – 31.12.2020)
Funding: European Commission grant number 667933-2